- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Aetna considers sale of PBM unit
Like other health insurers before it, Aetna considers selling off its PBM unit.
Aetna reportedly is considering the sale of its PBM unit.
“Our practice is not to comment on rumors or speculation,” Walt Cherniak, Aetna spokesman tells Managed Healthcare Executive. “Aetna remains committed to our integrated value proposition and clinical integration of pharmacy benefits remains a core element of Aetna's strategy. We believe our integration strategy continues to differentiate us in the marketplace. We are always willing to explore options that could add value to our shareholders and customers.”
Selling a health insurer's PBM is a good short-term solution to raising cash and improving fiscal outcome for the year, according to Robert Taketomo, PharmD, president and CEO of Ventegra in Glendale, Calif. “However, it removes an important tool for managing healthcare cost from the arsenal of that health insurer, and may be indicative of the longer-term strategy and direction of that insurer,” Taketomo says.
“If an insurer is committed to offering viable health plans, then control over their own PBM is critical. If an insurer is transitioning into a role as third-party administrator, then owning a PBM is not as critical,” he continues.
WellPoint sold its PBM to Express Scripts back in April for $4.7 billion.
A Conversation With Greg Baker, RPh, CEO of AffirmedRx
March 31st 2024Greg Baker, CEO of AffirmedRx, describes his early career, shares some of his critical opinions about the pharmacy benefit management (PBM) industry and how, in his view, his company is offering a better alternative.
Read More
Extending the Capabilities of the EHR Through Automation
August 2nd 2023Welcome back to another episode of "Tuning In to the C-Suite," where Briana Contreras, an editor of Managed Healthcare Executive, had the pleasure of chatting with Cindy Gaines, chief clinical transformation officer at Lumeon.
Listen
Florida Gets the OK. But Will Drug Importation from Canada Actually Happen?
March 5th 2024Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.
Read More
The deliberate disconnection of Change Healthcare to ring fence a cyberattack entered its seventh day today. Prescribers are finding ways to get pharmacy claims processed, and UnitedHealth Group says disruption to the dispensing of prescriptions has been minimal. But independent pharmacies want more information and protection from financial consequences from pharmacy benefit managers.
Read More
